

Application No. 10/522,297 - - - - 2

RECEIVED  
CENTRAL FAX CENTER  
JUL 30 2007

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (previously presented): A modified molecule having the biological activity of human erythropoietin (EPO) and being substantially non-immunogenic or less immunogenic than any non-modified molecule having the same biological activity in an individual when used *in vivo*, wherein (i) the said loss of immunogenicity is achieved by removing one or more T-cell epitopes derived from the originally non-modified molecule and said T-cell epitopes are MHC class II ligands or peptide sequences which show the ability to stimulate or bind T-cells via presentation on class II,

(ii) said modified molecule, when tested as a whole protein in a biological human T-cell proliferation assay, exhibits a stimulation index (SI) smaller than the parental non-modified molecule and smaller than 2.0, and

(iii) said T-cell epitopes to be removed are located on strings of contiguous residues of the originally non-modified EPO molecule, the strings are selected from:

(a) RVLERYLLEAKEAENITTGCAEHCSLNENITVP (SEQ ID NO: 2; residues 10-42 of SEQ ID NO: 1),

(b) RGQALLVNSSQPWEPLQLHVDKAVSGLRSLTTL (SEQ ID NO: 3; residues 76-108 of SEQ ID NO: 1),

(c) RTTADTFRKLFVYSNFLRGKCLKLYTGEACRT (SEQ ID NO: 4; residues 131-163 of SEQ ID NO: 1).

Claims 2-20 (canceled).

Claim 21 (previously presented): An isolated polypeptide having the biological activity of native human erythropoietin and being less immunogenic to a human than native human erythropoietin, the polypeptide comprising the amino acid residue sequence of SEQ ID NO: 1 and including at least one amino acid residue substitution in at

Application No. 10/522,297 - - - - 3

least one epitope region of SEQ ID NO: 1 selected from the group consisting of (a) amino acid residues 10-42 of SEQ ID NO: 1, (b) amino acid residues 76-108 of SEQ ID NO: 1, and (c) amino acid residues 131-163 of SEQ ID NO: 1.

Claim 22 (previously presented): The isolated polypeptide of claim 21 wherein the at least one amino acid residue substitution in epitope region (a) is selected from the group consisting of Ile25Ala, Ile25Gly, Ile25Pro, Leu35Ala, Leu35Asp, Leu35Glu, Leu35Gly, Leu35His, Leu35Lys, Leu35Asn, Leu35Pro, Leu35Gln, Leu35Arg, Leu35Ser, and Leu35Thr.

Claim 23 (previously presented): The isolated polypeptide of claim 21 wherein the at least one amino acid residue substitution in epitope region (b) is selected from the group consisting of Trp88Thr, Trp88Ala, Trp88Gly, Leu91Ala, Leu91Asp, Leu91Glu, Leu91Gly, Leu91His, Leu91Lys, Leu91Asn, Leu91Pro, Leu91Gln, Leu91Arg, Ser, Leu91Thr, Leu93Ala, Leu93Asp, Leu93Glu, Leu93Gly, Leu93His, Leu93Lys, Leu93Asn, Leu93Pro, Leu93Gln, Leu93Arg, Leu93Ser, Leu93Thr, Val95Ala, Val95Asp, Val95Glu, Val95Gly, Val95His, Val95Lys, Val95Asn, Val95Pro, Val95Gln, Val95Arg, Val95Ser, and Val95Thr.

Claim 24 (previously presented): The isolated polypeptide of claim 21 wherein the at least one amino acid residue substitution in epitope region (c) is selected from the group consisting of: Ile141Thr, Phe142Ala, Phe142Gly, Phe142Pro, Val144Thr, Tyr145Ala, Tyr145Gly, Tyr145Pro, Phe148Ala, Phe148Gly, Phe148Pro, Leu149Ala, Leu149Asp, Leu149Gly, Leu149His, Leu149Lys, Leu149Asn, Leu149Pro, Leu149Gln, Leu149Arg, Leu149Ser, Leu149Thr, Leu153Ala, Leu153Asp, Leu153Glu, Leu153Gly, Leu153His, Leu153Lys, Leu153Asn, Leu153Pro, Leu153Gln, Leu153Arg, Leu153Ser, and Leu153Thr.

Claim 25 (previously presented): An isolated polypeptide having the biological activity of native human erythropoietin and being less immunogenic to a human than native human erythropoietin, the polypeptide comprising the amino acid residue sequence of SEQ ID NO: 1 and including at least one amino acid residue substitution in at least one epitope region of SEQ ID NO: 1 selected from the group consisting of (R1) amino acid residues 19-39 of SEQ ID NO: 1, (R2) amino acid residues 76-96 of SEQ ID NO: 1, and (R3) amino acid residues 137-157 of SEQ ID NO: 1.

Claim 26 (previously presented): The isolated polypeptide of claim 25 wherein the at least one amino acid residue substitution in epitope region (R1) is selected from the

Application No. 10/522,297 - - - - 4

group consisting of Ile25Ala, Ile25Gly, Ile25Pro, Leu35Ala, Leu35Asp, Leu35Glu, Leu35Gly, Leu35His, Leu35Lys, Leu35Asn, Leu35Pro, Leu35Gln, Leu35Arg, Leu35Ser, and Leu35Thr.

Claim 27 (previously presented): The isolated polypeptide of claim 25 wherein the at least one amino acid residue substitution in epitope region (R2) is selected from the group consisting of Trp88Thr, Trp88Ala, Trp88Gly, Leu91Ala, Leu91Asp, Leu91Glu, Leu91Gly, Leu91His, Leu91Lys, Leu91Asn, Leu91Pro, Leu91Gln, Leu91Arg, Ser, Leu91Thr, Leu93Ala, Leu93Asp, Leu93Glu, Leu93Gly, Leu93His, Leu93Lys, Leu93Asn, Leu93Pro, Leu93Gln, Leu93Arg, Leu93Ser, Leu93Thr, Val95Ala, Val95Asp, Val95Glu, Val95Gly, Val95His, Val95Lys, Val95Asn, Val95Pro, Val95Gln, Val95Arg, Val95Ser, and Val95Thr.

Claim 28 (previously presented): The isolated polypeptide of claim 25 wherein the at least one amino acid residue substitution in epitope region (R3) is selected from the group consisting of: Ile141Thr, Phe142Ala, Phe142Gly, Phe142Pro, Val144Thr, Tyr145Ala, Tyr145Gly, Tyr145Pro, Phe148Ala, Phe148Gly, Phe148Pro, Leu149Ala, Leu149Asp, Leu149Gly, Leu149His, Leu149Lys, Leu149Asn, Leu149Pro, Leu149Gln, Leu149Arg, Leu149Ser, Leu149Thr, Leu153Ala, Leu153Asp, Leu153Glu, Leu153Gly, Leu153His, Leu153Lys, Leu153Asn, Leu153Pro, Leu153Gln, Leu153Arg, Leu153Ser, and Leu153Thr.

Claim 29 (previously presented): An isolated polypeptide comprising the amino acid residue sequence of SEQ ID NO: 1 and including at least one amino acid residue substitution in SEQ ID NO: 1 selected from the group consisting of: Ile25Ala, Ile25Gly, Ile25Pro, Leu35Ala, Leu35Asp, Leu35Glu, Leu35Gly, Leu35His, Leu35Lys, Leu35Asn, Leu35Pro, Leu35Gln, Leu35Arg, Leu35Ser, Leu35Thr, Trp88Thr, Trp88Ala, Trp88Gly, Leu91Ala, Leu91Asp, Leu91Glu, Leu91Gly, Leu91His, Leu91Lys, Leu91Asn, Leu91Pro, Leu91Gln, Leu91Arg, Ser, Leu91Thr, Leu93Ala, Leu93Asp, Leu93Glu, Leu93Gly, Leu93His, Leu93Lys, Leu93Asn, Leu93Pro, Leu93Gln, Leu93Arg, Leu93Ser, Leu93Thr, Val95Ala, Val95Asp, Val95Glu, Val95Gly, Val95His, Val95Lys, Val95Asn, Val95Pro, Val95Gln, Val95Arg, Val95Ser, Val95Thr, Ile141Thr, Phe142Ala, Phe142Gly, Phe142Pro, Val144Thr, Tyr145Ala, Tyr145Gly, Tyr145Pro, Phe148Ala, Phe148Gly, Phe148Pro, Leu149Ala, Leu149Asp, Leu149Gly, Leu149His, Leu149Lys, Leu149Asn, Leu149Pro, Leu149Gln, Leu149Arg, Leu149Ser, Leu149Thr, Leu153Ala, Leu153Asp, Leu153Glu, Leu153Gly,

Application No. 10/522,297 - - - - 5

Leu153His, Leu153Lys, Leu153Asn, Leu153Pro, Leu153Gln, Leu153Arg, Leu153Ser, and Leu153Thr.

Claim 30 (previously presented): An isolated nucleic acid that encodes a polypeptide of claim 21.

Claim 31 (previously presented): An isolated nucleic acid that encodes a polypeptide of claim 25.

Claim 32 (previously presented): An isolated nucleic acid that encodes a polypeptide of claim 29.

Claim 33 (previously presented): A pharmaceutical composition comprising a polypeptide of claim 21 in a pharmaceutically acceptable carrier therefor.

Claim 34 (previously presented): A pharmaceutical composition comprising a polypeptide of claim 25 in a pharmaceutically acceptable carrier therefor.

Claim 35 (previously presented): A pharmaceutical composition comprising a polypeptide of claim 29 in a pharmaceutically acceptable carrier therefor.

Claim 36 (previously presented): The isolated polypeptide of claim 21 wherein the polypeptide exhibits a stimulation index of less than 2 when tested in a biological human T-cell proliferation assay.

Claim 37 (previously presented): The isolated polypeptide of claim 21 wherein the polypeptide exhibits a stimulation index of less than 1.8 when tested in a biological human T-cell proliferation assay.

Claim 38 (new): The isolated polypeptide of claim 21 wherein the at least one amino acid residue substitution in epitope region (c) is Phe142Ala or Val144Thr or Tyr145Pro.